Addressing screening failures in early-phase clinical trials in oncology: impact on patient outcomes and strategies for improvement
Main reasons for SF were radiological, biological and clinical. Therefore, referring patients with brain scan and laboratory results may help reduce SF rates. Current criteria deem ineligible 47.5% of patients who are alive at 6 months, questioning their accuracy for patient selection in EPT whose aim is to evaluate drug tolerance/activity.
Authors
- E. Magne (ORCID: https://orcid.org/0000-0003-4215-8669)
- Amélie Lusque (ORCID: https://orcid.org/0000-0001-9691-5536)
- Philippe A. Cassier (ORCID: https://orcid.org/0000-0003-3857-1688)
- B. Hanvic
- Kheireddine Ouali (ORCID: https://orcid.org/0000-0002-5842-0767)
- S. Clementei
- Loïc Verlingue (ORCID: https://orcid.org/0000-0002-5694-4022)
- C. Massard
- Benoît Allignet (ORCID: https://orcid.org/0000-0001-7275-0773)
- C Gomez-Roca
- Bertille Segier (ORCID: https://orcid.org/0009-0005-3492-3780)
- J-P. Delord
- Capucine Baldini
- Iphigenia Korakis
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Institut Gustave Roussy (FR)
- Centre Léon Bérard (FR)
- Institut Claudius Regaud (FR)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105331
- Citations
- 1
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.94